HER2 expression in upper tract urothelial carcinoma and the relationship with clinicopathological characteristics—an analysis of 155 patients in Southwest China
Objective We aimed to evaluate the expression of HER2 in patients with upper tract urothelial carcinoma (UTUC) in Southwest China by using a relatively large cohort, and to determine the relationship between HER2 expression and clinicopathological characters. Materials and methods We retrospectively...
Gespeichert in:
| Veröffentlicht in: | World journal of urology 2024-09, Vol.42 (1), p.521, Article 521 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 521 |
| container_title | World journal of urology |
| container_volume | 42 |
| creator | Ye, Jianjun Chen, Zeyu Liao, Xinyang Wang, Xingyuan Zhang, Chichen Han, Ping Wei, Qiang Bao, Yige |
| description | Objective
We aimed to evaluate the expression of HER2 in patients with upper tract urothelial carcinoma (UTUC) in Southwest China by using a relatively large cohort, and to determine the relationship between HER2 expression and clinicopathological characters.
Materials and methods
We retrospectively enrolled the clinical data of 155 UTUC patients who have undergone radical nephroureterectomy (RNU) from March 2019 to September 2022. HER2 expression was assessed using immunohistochemistry and scored according to the HercepTest (Scores of 0 or 1 + were considered as negative and 2 + or 3 + as positive). Tumor molecular phenotype was classified by the panel of CK20, CK5/6, and CD44.
Results
HER2 was overexpressed in 55 (35.5%) patients. It was associated with pathologic characteristics such as grade (p = 0.017), tumor molecular phenotype (p |
| doi_str_mv | 10.1007/s00345-024-05222-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3104538557</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3104360948</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-4774a7abf3b69db64fa93367610db8e98c4032a5ab2f5e6a6c6fbd54e3a04e193</originalsourceid><addsrcrecordid>eNp9kU1u1TAUhS0EoqWwAQbIEhMmAf87GaKnQpEqIbUwjm4cp3GVZwfbUemMRXQFXRorwSGFIgYdXev6O-fo6iD0kpK3lBD9LhHChawIExWRjLGqfoQOqeC8qjVTj_95H6BnKV0SQrUi8ik64A3TVCp2iG5Pjs8Ytt_naFNywWPn8TLPNuIcwWS8xJBHOzmYsIFonA97wOB7XLY42glyEaXRzfjK5RGbyXlnwgx5DFO4cGbVjbBa2ehSdib9_HEDvljAdJ1cwmHAVEpcFM76nNb887Dk8cqmjHej8_AcPRlgSvbF3TxCXz8cf9mdVKefP37avT-tDJMqV0JrARq6gXeq6TslBmg4V1pR0ne1bWojCGcgoWODtAqUUUPXS2E5EGFpw4_Qm813juHbUuLbvUvGThN4G5bUckqE5LWUuqCv_0MvwxLLSRvFFWlEXSi2USaGlKId2jm6PcTrlpJ2bbDdGmxLg-3vBttV9OrOeun2tv8r-VNZAfgGpPLlL2y8z37A9hdzSap9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3104360948</pqid></control><display><type>article</type><title>HER2 expression in upper tract urothelial carcinoma and the relationship with clinicopathological characteristics—an analysis of 155 patients in Southwest China</title><source>MEDLINE</source><source>SpringerLink_现刊</source><creator>Ye, Jianjun ; Chen, Zeyu ; Liao, Xinyang ; Wang, Xingyuan ; Zhang, Chichen ; Han, Ping ; Wei, Qiang ; Bao, Yige</creator><creatorcontrib>Ye, Jianjun ; Chen, Zeyu ; Liao, Xinyang ; Wang, Xingyuan ; Zhang, Chichen ; Han, Ping ; Wei, Qiang ; Bao, Yige</creatorcontrib><description>Objective
We aimed to evaluate the expression of HER2 in patients with upper tract urothelial carcinoma (UTUC) in Southwest China by using a relatively large cohort, and to determine the relationship between HER2 expression and clinicopathological characters.
Materials and methods
We retrospectively enrolled the clinical data of 155 UTUC patients who have undergone radical nephroureterectomy (RNU) from March 2019 to September 2022. HER2 expression was assessed using immunohistochemistry and scored according to the HercepTest (Scores of 0 or 1 + were considered as negative and 2 + or 3 + as positive). Tumor molecular phenotype was classified by the panel of CK20, CK5/6, and CD44.
Results
HER2 was overexpressed in 55 (35.5%) patients. It was associated with pathologic characteristics such as grade (p = 0.017), tumor molecular phenotype (p < 0.001) and Ki-67 expression (p = 0.017). On univariate and multivariable logistic regression analysis, HER2 overexpression remained associated with higher grade (HR, 10.6; 95% CI 1.0–112.6; p = 0.050) and luminal molecular phenotype (HR, 8.0; 95% CI 1,6–38.4; p = 0.010). During disease progression after nephroureterectomy, the phenotype of the tumor might change and a switch phenomenon in phenotype after recurrence in the bladder was reported.
Conclusion
According to our study, in Southwest China, one-third of UTUC patients overexpressed HER2. Tumors with high grade or luminal phenotype tended to be HER2 positive. HER2 may represent a promising target for therapy in UTUC.</description><identifier>ISSN: 1433-8726</identifier><identifier>ISSN: 0724-4983</identifier><identifier>EISSN: 1433-8726</identifier><identifier>DOI: 10.1007/s00345-024-05222-8</identifier><identifier>PMID: 39271562</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Carcinoma, Transitional Cell - genetics ; Carcinoma, Transitional Cell - metabolism ; Carcinoma, Transitional Cell - pathology ; Carcinoma, Transitional Cell - surgery ; CD44 antigen ; China - epidemiology ; ErbB-2 protein ; Female ; Genotype & phenotype ; Humans ; Immunohistochemistry ; Kidney Neoplasms - genetics ; Kidney Neoplasms - metabolism ; Kidney Neoplasms - pathology ; Kidney Neoplasms - surgery ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Nephrology ; Oncology ; Phenotypes ; Receptor, ErbB-2 - genetics ; Receptor, ErbB-2 - metabolism ; Retrospective Studies ; Tumors ; Ureteral Neoplasms - genetics ; Ureteral Neoplasms - metabolism ; Ureteral Neoplasms - pathology ; Ureteral Neoplasms - surgery ; Urology ; Urothelial carcinoma</subject><ispartof>World journal of urology, 2024-09, Vol.42 (1), p.521, Article 521</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-4774a7abf3b69db64fa93367610db8e98c4032a5ab2f5e6a6c6fbd54e3a04e193</cites><orcidid>0000-0002-1827-5542</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00345-024-05222-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00345-024-05222-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39271562$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ye, Jianjun</creatorcontrib><creatorcontrib>Chen, Zeyu</creatorcontrib><creatorcontrib>Liao, Xinyang</creatorcontrib><creatorcontrib>Wang, Xingyuan</creatorcontrib><creatorcontrib>Zhang, Chichen</creatorcontrib><creatorcontrib>Han, Ping</creatorcontrib><creatorcontrib>Wei, Qiang</creatorcontrib><creatorcontrib>Bao, Yige</creatorcontrib><title>HER2 expression in upper tract urothelial carcinoma and the relationship with clinicopathological characteristics—an analysis of 155 patients in Southwest China</title><title>World journal of urology</title><addtitle>World J Urol</addtitle><addtitle>World J Urol</addtitle><description>Objective
We aimed to evaluate the expression of HER2 in patients with upper tract urothelial carcinoma (UTUC) in Southwest China by using a relatively large cohort, and to determine the relationship between HER2 expression and clinicopathological characters.
Materials and methods
We retrospectively enrolled the clinical data of 155 UTUC patients who have undergone radical nephroureterectomy (RNU) from March 2019 to September 2022. HER2 expression was assessed using immunohistochemistry and scored according to the HercepTest (Scores of 0 or 1 + were considered as negative and 2 + or 3 + as positive). Tumor molecular phenotype was classified by the panel of CK20, CK5/6, and CD44.
Results
HER2 was overexpressed in 55 (35.5%) patients. It was associated with pathologic characteristics such as grade (p = 0.017), tumor molecular phenotype (p < 0.001) and Ki-67 expression (p = 0.017). On univariate and multivariable logistic regression analysis, HER2 overexpression remained associated with higher grade (HR, 10.6; 95% CI 1.0–112.6; p = 0.050) and luminal molecular phenotype (HR, 8.0; 95% CI 1,6–38.4; p = 0.010). During disease progression after nephroureterectomy, the phenotype of the tumor might change and a switch phenomenon in phenotype after recurrence in the bladder was reported.
Conclusion
According to our study, in Southwest China, one-third of UTUC patients overexpressed HER2. Tumors with high grade or luminal phenotype tended to be HER2 positive. HER2 may represent a promising target for therapy in UTUC.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Carcinoma, Transitional Cell - genetics</subject><subject>Carcinoma, Transitional Cell - metabolism</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Carcinoma, Transitional Cell - surgery</subject><subject>CD44 antigen</subject><subject>China - epidemiology</subject><subject>ErbB-2 protein</subject><subject>Female</subject><subject>Genotype & phenotype</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Kidney Neoplasms - genetics</subject><subject>Kidney Neoplasms - metabolism</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kidney Neoplasms - surgery</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Oncology</subject><subject>Phenotypes</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Retrospective Studies</subject><subject>Tumors</subject><subject>Ureteral Neoplasms - genetics</subject><subject>Ureteral Neoplasms - metabolism</subject><subject>Ureteral Neoplasms - pathology</subject><subject>Ureteral Neoplasms - surgery</subject><subject>Urology</subject><subject>Urothelial carcinoma</subject><issn>1433-8726</issn><issn>0724-4983</issn><issn>1433-8726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1u1TAUhS0EoqWwAQbIEhMmAf87GaKnQpEqIbUwjm4cp3GVZwfbUemMRXQFXRorwSGFIgYdXev6O-fo6iD0kpK3lBD9LhHChawIExWRjLGqfoQOqeC8qjVTj_95H6BnKV0SQrUi8ik64A3TVCp2iG5Pjs8Ytt_naFNywWPn8TLPNuIcwWS8xJBHOzmYsIFonA97wOB7XLY42glyEaXRzfjK5RGbyXlnwgx5DFO4cGbVjbBa2ehSdib9_HEDvljAdJ1cwmHAVEpcFM76nNb887Dk8cqmjHej8_AcPRlgSvbF3TxCXz8cf9mdVKefP37avT-tDJMqV0JrARq6gXeq6TslBmg4V1pR0ne1bWojCGcgoWODtAqUUUPXS2E5EGFpw4_Qm813juHbUuLbvUvGThN4G5bUckqE5LWUuqCv_0MvwxLLSRvFFWlEXSi2USaGlKId2jm6PcTrlpJ2bbDdGmxLg-3vBttV9OrOeun2tv8r-VNZAfgGpPLlL2y8z37A9hdzSap9</recordid><startdate>20240913</startdate><enddate>20240913</enddate><creator>Ye, Jianjun</creator><creator>Chen, Zeyu</creator><creator>Liao, Xinyang</creator><creator>Wang, Xingyuan</creator><creator>Zhang, Chichen</creator><creator>Han, Ping</creator><creator>Wei, Qiang</creator><creator>Bao, Yige</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1827-5542</orcidid></search><sort><creationdate>20240913</creationdate><title>HER2 expression in upper tract urothelial carcinoma and the relationship with clinicopathological characteristics—an analysis of 155 patients in Southwest China</title><author>Ye, Jianjun ; Chen, Zeyu ; Liao, Xinyang ; Wang, Xingyuan ; Zhang, Chichen ; Han, Ping ; Wei, Qiang ; Bao, Yige</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-4774a7abf3b69db64fa93367610db8e98c4032a5ab2f5e6a6c6fbd54e3a04e193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Carcinoma, Transitional Cell - genetics</topic><topic>Carcinoma, Transitional Cell - metabolism</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Carcinoma, Transitional Cell - surgery</topic><topic>CD44 antigen</topic><topic>China - epidemiology</topic><topic>ErbB-2 protein</topic><topic>Female</topic><topic>Genotype & phenotype</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Kidney Neoplasms - genetics</topic><topic>Kidney Neoplasms - metabolism</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kidney Neoplasms - surgery</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Oncology</topic><topic>Phenotypes</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Retrospective Studies</topic><topic>Tumors</topic><topic>Ureteral Neoplasms - genetics</topic><topic>Ureteral Neoplasms - metabolism</topic><topic>Ureteral Neoplasms - pathology</topic><topic>Ureteral Neoplasms - surgery</topic><topic>Urology</topic><topic>Urothelial carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ye, Jianjun</creatorcontrib><creatorcontrib>Chen, Zeyu</creatorcontrib><creatorcontrib>Liao, Xinyang</creatorcontrib><creatorcontrib>Wang, Xingyuan</creatorcontrib><creatorcontrib>Zhang, Chichen</creatorcontrib><creatorcontrib>Han, Ping</creatorcontrib><creatorcontrib>Wei, Qiang</creatorcontrib><creatorcontrib>Bao, Yige</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>World journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ye, Jianjun</au><au>Chen, Zeyu</au><au>Liao, Xinyang</au><au>Wang, Xingyuan</au><au>Zhang, Chichen</au><au>Han, Ping</au><au>Wei, Qiang</au><au>Bao, Yige</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HER2 expression in upper tract urothelial carcinoma and the relationship with clinicopathological characteristics—an analysis of 155 patients in Southwest China</atitle><jtitle>World journal of urology</jtitle><stitle>World J Urol</stitle><addtitle>World J Urol</addtitle><date>2024-09-13</date><risdate>2024</risdate><volume>42</volume><issue>1</issue><spage>521</spage><pages>521-</pages><artnum>521</artnum><issn>1433-8726</issn><issn>0724-4983</issn><eissn>1433-8726</eissn><abstract>Objective
We aimed to evaluate the expression of HER2 in patients with upper tract urothelial carcinoma (UTUC) in Southwest China by using a relatively large cohort, and to determine the relationship between HER2 expression and clinicopathological characters.
Materials and methods
We retrospectively enrolled the clinical data of 155 UTUC patients who have undergone radical nephroureterectomy (RNU) from March 2019 to September 2022. HER2 expression was assessed using immunohistochemistry and scored according to the HercepTest (Scores of 0 or 1 + were considered as negative and 2 + or 3 + as positive). Tumor molecular phenotype was classified by the panel of CK20, CK5/6, and CD44.
Results
HER2 was overexpressed in 55 (35.5%) patients. It was associated with pathologic characteristics such as grade (p = 0.017), tumor molecular phenotype (p < 0.001) and Ki-67 expression (p = 0.017). On univariate and multivariable logistic regression analysis, HER2 overexpression remained associated with higher grade (HR, 10.6; 95% CI 1.0–112.6; p = 0.050) and luminal molecular phenotype (HR, 8.0; 95% CI 1,6–38.4; p = 0.010). During disease progression after nephroureterectomy, the phenotype of the tumor might change and a switch phenomenon in phenotype after recurrence in the bladder was reported.
Conclusion
According to our study, in Southwest China, one-third of UTUC patients overexpressed HER2. Tumors with high grade or luminal phenotype tended to be HER2 positive. HER2 may represent a promising target for therapy in UTUC.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>39271562</pmid><doi>10.1007/s00345-024-05222-8</doi><orcidid>https://orcid.org/0000-0002-1827-5542</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1433-8726 |
| ispartof | World journal of urology, 2024-09, Vol.42 (1), p.521, Article 521 |
| issn | 1433-8726 0724-4983 1433-8726 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3104538557 |
| source | MEDLINE; SpringerLink_现刊 |
| subjects | Adult Aged Aged, 80 and over Carcinoma, Transitional Cell - genetics Carcinoma, Transitional Cell - metabolism Carcinoma, Transitional Cell - pathology Carcinoma, Transitional Cell - surgery CD44 antigen China - epidemiology ErbB-2 protein Female Genotype & phenotype Humans Immunohistochemistry Kidney Neoplasms - genetics Kidney Neoplasms - metabolism Kidney Neoplasms - pathology Kidney Neoplasms - surgery Male Medicine Medicine & Public Health Middle Aged Nephrology Oncology Phenotypes Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Retrospective Studies Tumors Ureteral Neoplasms - genetics Ureteral Neoplasms - metabolism Ureteral Neoplasms - pathology Ureteral Neoplasms - surgery Urology Urothelial carcinoma |
| title | HER2 expression in upper tract urothelial carcinoma and the relationship with clinicopathological characteristics—an analysis of 155 patients in Southwest China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T09%3A17%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HER2%20expression%20in%20upper%20tract%20urothelial%20carcinoma%20and%20the%20relationship%20with%20clinicopathological%20characteristics%E2%80%94an%20analysis%20of%20155%20patients%20in%20Southwest%20China&rft.jtitle=World%20journal%20of%20urology&rft.au=Ye,%20Jianjun&rft.date=2024-09-13&rft.volume=42&rft.issue=1&rft.spage=521&rft.pages=521-&rft.artnum=521&rft.issn=1433-8726&rft.eissn=1433-8726&rft_id=info:doi/10.1007/s00345-024-05222-8&rft_dat=%3Cproquest_cross%3E3104360948%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3104360948&rft_id=info:pmid/39271562&rfr_iscdi=true |